Biologics in Therapy View Homepage


Ontology type: schema:Periodical      Open Access: True


Journal Info

START YEAR

2011

PUBLISHER

Springer Healthcare

LANGUAGE

en

HOMEPAGE

http://link.springer.com/journal/13554

Recent publications latest 20 shown

  • 2015-12 Publisher’s Note
  • 2014-12 One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
  • 2014-12 To the Editor; A Commentary on “Switching From Originator to Biosimilar Human Growth Hormone Using a Dialogue Teamwork: Single-Center Experience From Sweden”
  • 2014-12 Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures
  • 2014-12 Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening
  • 2014-12 Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting
  • 2014-12 Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
  • 2014-12 Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
  • 2014-12 Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
  • 2013-12 Golimumab: A Novel Anti-Tumor Necrosis Factor
  • 2013-12 The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis
  • 2013-06 Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
  • 2013-06 Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept
  • 2013-06 Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
  • 2013-06 Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands
  • 2013-06 Brentuximab Vedotin in CD30+ Lymphomas
  • 2012-01 Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases
  • 2012-01 Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency
  • 2012-01 Erratum to: Human Plasma-Derived, Nanofiltered C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting From C1-Inhibitor Deficiency
  • 2012-01 Axitinib in Metastatic Renal Cell Carcinoma
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33002", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Internal Medicine", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33160", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Oncology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33170", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Rheumatology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33061", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Gastroenterology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33053", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Endocrinology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33096", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Infectious Diseases", 
            "type": "DefinedTerm"
          }
        ], 
        "description": "

    Please note: Biologics in Therapy is no longer accepting submissions. For information on our other journals or for any other enquiries please contact adisrapidplus@springer.com.

    Over recent years biotechnology has been instrumental in the development of key medicines such as monoclonal antibodies for the treatment of cancer and autoimmune conditions such as rheumatoid arthritis and psoriasis, human insulin for the treatment of diabetes, and the cloning of erythropoietin to stimulate the production of red blood cells in the treatment of chronic anemia.

    In this fast-paced area of medical research, we feel it is of utmost importance for specialist and generalist healthcare professionals alike to have access to the most up to date and relevant research, including analysis on how this research translates to treatment strategies in clinical practice. Each biological therapy has a highly sensitive and specific mode of action in relation to particular indications and therapy areas, and as such it was felt that research in these areas would be better suited to therapeutic area-specific journals, where data and information will gain optimal exposure and recognition in that particular field to the most relevant audience.

    In accordance with this approach,\u00a0Biologics in Therapy\u00a0will be closing at the end of 2015. The Adis journal portfolio continues to welcome content relating to the discovery, development, and use of biological and biosimilar therapies in all medical fields, including high-quality preclinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of such therapies. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged throughout the portfolio.

    -----

    Biologics in\u00a0Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3\u20134 weeks from acceptance). The journal is dedicated to the publication of high-quality preclinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of biological therapies. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged.

    The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, and short communications. The journal appeals to a global audience and receives submissions from all over the world.

    Moving forward from traditional publishing, Biologics\u00a0in Therapy offers a range of additional enhanced features designed to increase visibility, readership, and the educational value of the content. Each paper is accompanied by a bulleted Summary slide, giving a time-efficient overview of the content to a wide readership. Articles also have the option to include slide sets, videos, animations, and/or interactive learning resources. All enhanced features are open access and are peer reviewed to the same high standard as the article itself.

    Biologics\u00a0in Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/2.5.

    ", "id": "sg:journal.1049068", "inLanguage": [ "en" ], "isAccessibleForFree": true, "issn": [ "2195-5840", "2190-9164" ], "license": "Fully Open Access", "name": "Biologics in Therapy", "productId": [ { "name": "dimensions_id", "type": "PropertyValue", "value": [ "49068" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "13554" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "2013243668" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "101617621" ] } ], "publisher": { "name": "Springer Healthcare", "type": "Organization" }, "publisherImprint": "Adis", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1049068" ], "sdDataset": "journals", "sdDatePublished": "2021-01-20T04:59", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///pack/app/journals_20190313_sn_only.jsonl", "startYear": "2011", "type": "Periodical", "url": "http://link.springer.com/journal/13554" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1049068'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1049068'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1049068'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1049068'


     

    This table displays all metadata directly associated to this object as RDF triples.

    62 TRIPLES      19 PREDICATES      29 URIs      19 LITERALS      6 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1049068 schema:about sg:ontologies/product-market-codes/H33002
    2 sg:ontologies/product-market-codes/H33053
    3 sg:ontologies/product-market-codes/H33061
    4 sg:ontologies/product-market-codes/H33096
    5 sg:ontologies/product-market-codes/H33160
    6 sg:ontologies/product-market-codes/H33170
    7 schema:description <p><b>Please note: </b><i>Biologics in Therapy </i>is no longer accepting submissions. For information on our other journals or for any other enquiries please contact adisrapidplus@springer.com.</p><p>Over recent years biotechnology has been instrumental in the development of key medicines such as monoclonal antibodies for the treatment of cancer and autoimmune conditions such as rheumatoid arthritis and psoriasis, human insulin for the treatment of diabetes, and the cloning of erythropoietin to stimulate the production of red blood cells in the treatment of chronic anemia.</p><p>In this fast-paced area of medical research, we feel it is of utmost importance for specialist and generalist healthcare professionals alike to have access to the most up to date and relevant research, including analysis on how this research translates to treatment strategies in clinical practice. Each biological therapy has a highly sensitive and specific mode of action in relation to particular indications and therapy areas, and as such it was felt that research in these areas would be better suited to therapeutic area-specific journals, where data and information will gain optimal exposure and recognition in that particular field to the most relevant audience.</p><p>In accordance with this approach, <i>Biologics in Therapy</i> will be closing at the end of 2015. The Adis journal portfolio continues to welcome content relating to the discovery, development, and use of biological and biosimilar therapies in all medical fields, including high-quality preclinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of such therapies. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged throughout the portfolio.</p><p>-----</p><p><i>Biologics in Therapy</i> is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality preclinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of biological therapies. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged.</p><p>The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, and short communications. The journal appeals to a global audience and receives submissions from all over the world.</p><p>Moving forward from traditional publishing, <i>Biologics in Therapy</i> offers a range of additional enhanced features designed to increase visibility, readership, and the educational value of the content. Each paper is accompanied by a bulleted Summary slide, giving a time-efficient overview of the content to a wide readership. Articles also have the option to include slide sets, videos, animations, and/or interactive learning resources. All enhanced features are open access and are peer reviewed to the same high standard as the article itself.</p><p><i>Biologics in Therapy</i> is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/2.5.</p>
    8 schema:inLanguage en
    9 schema:isAccessibleForFree true
    10 schema:issn 2190-9164
    11 2195-5840
    12 schema:license Fully Open Access
    13 schema:name Biologics in Therapy
    14 schema:productId N21f56711f724411d9bdc7ae288595534
    15 N22aa63ce1bdb49e396c77b05d8bd9946
    16 N851bb3b58e3e42caa4296cdbf3f0e136
    17 Nddba1bff68f84c009b95af7ec1320664
    18 schema:publisher Ncb07ff77e31242548c26718a7f7bdc8a
    19 schema:publisherImprint Adis
    20 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1049068
    21 schema:sdDatePublished 2021-01-20T04:59
    22 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    23 schema:sdPublisher Nc56ee639ae51405ba267ea232151c612
    24 schema:startYear 2011
    25 schema:url http://link.springer.com/journal/13554
    26 sgo:license sg:explorer/license/
    27 sgo:sdDataset journals
    28 rdf:type schema:Periodical
    29 N21f56711f724411d9bdc7ae288595534 schema:name springer_id
    30 schema:value 13554
    31 rdf:type schema:PropertyValue
    32 N22aa63ce1bdb49e396c77b05d8bd9946 schema:name lccn_id
    33 schema:value 2013243668
    34 rdf:type schema:PropertyValue
    35 N851bb3b58e3e42caa4296cdbf3f0e136 schema:name nlm_unique_id
    36 schema:value 101617621
    37 rdf:type schema:PropertyValue
    38 Nc56ee639ae51405ba267ea232151c612 schema:name Springer Nature - SN SciGraph project
    39 rdf:type schema:Organization
    40 Ncb07ff77e31242548c26718a7f7bdc8a schema:name Springer Healthcare
    41 rdf:type schema:Organization
    42 Nddba1bff68f84c009b95af7ec1320664 schema:name dimensions_id
    43 schema:value 49068
    44 rdf:type schema:PropertyValue
    45 sg:ontologies/product-market-codes/H33002 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    46 schema:name Internal Medicine
    47 rdf:type schema:DefinedTerm
    48 sg:ontologies/product-market-codes/H33053 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    49 schema:name Endocrinology
    50 rdf:type schema:DefinedTerm
    51 sg:ontologies/product-market-codes/H33061 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    52 schema:name Gastroenterology
    53 rdf:type schema:DefinedTerm
    54 sg:ontologies/product-market-codes/H33096 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    55 schema:name Infectious Diseases
    56 rdf:type schema:DefinedTerm
    57 sg:ontologies/product-market-codes/H33160 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    58 schema:name Oncology
    59 rdf:type schema:DefinedTerm
    60 sg:ontologies/product-market-codes/H33170 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    61 schema:name Rheumatology
    62 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...